GlassScriptPhysician profile
Shamsuddin Khwaja
NPI 1487619284
$16,382.46
in general payments reported to CMS, 2019-2025
44 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,196 · 2020: $1,714 · 2021: $2,731 · 2022: $2,320 · 2023: $1,913 · 2024: $2,694 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,877 · Travel and Lodging: $470 · Education: $74.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,876.97 |
| Travel and Lodging | $470.28 |
| Education | $74.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,286.58 | 2019-2025 | Ajovy, Austedo, Austedo Xr |
| Emd Serono, INC. | $2,273.20 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,735.87 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,080.87 | 2019-2025 | |
| Abiomed | $780.28 | 2025 | |
| Biogen, INC. | $720.62 | 2019-2025 | Tysabri, Vumerity |
| Argenx US, INC. | $634.97 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $634.05 | 2019-2025 | Uplizna |
| Sk Life Science, INC. | $571.61 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $495.01 | 2020-2022 | |
| Lilly USA, LLC | $474.63 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Kyowa Kirin, INC. | $432.38 | 2020-2024 | Nourianz |
| Pfizer INC. | $416.30 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $412.73 | 2020-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $369.95 | 2020-2024 | Ongentys, Ingrezza |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $309.66 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceuticals, INC. | $282.77 | 2021 | |
| Supernus Pharmaceuticals, INC. | $250.26 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $248.63 | 2021-2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $242.31 | 2021-2024 | Zeposia |
| Lundbeck LLC | $222.85 | 2020-2024 | Rexulti, Vyepti |
| Allergan, INC. | $193.62 | 2019-2021 | |
| Eisai INC. | $127.49 | 2024-2025 | |
| Mdd US Operations, LLC | $124.96 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $124.44 | 2020-2022 | |
| Medtronic, INC. | $119.31 | 2023 | Intellis Adaptivestim, Vanta Adaptivestim |
| Ucb, INC. | $119.06 | 2019-2025 | Briviact |
| Sumitomo Pharma America, INC. | $65.15 | 2023-2024 | Aptiom |
| Otsuka America Pharmaceutical, INC. | $64.36 | 2024-2025 | Rexulti |
| Tg Therapeutics, INC. | $63.48 | 2025 | |
| Amneal Pharmaceuticals LLC | $62.97 | 2019-2020 | |
| Csl Behring | $60.12 | 2025 | Hizentra |
| Acadia Pharmaceuticals INC | $59.68 | 2024 | Nuplazid |
| Cala Health, INC. | $53.13 | 2025 | Cala Kiq |
| Idorsia Pharmaceuticals US INC | $35.54 | 2023 | Quviviq |
| Medtronic Vascular, INC. | $34.96 | 2019-2020 | |
| Grt US Holding, INC. | $34.52 | 2022 | |
| Janssen Pharmaceuticals, INC | $34.25 | 2022 | |
| Mallinckrodt Enterprises LLC | $25.25 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.28 | 2019-2020 | |
| Ge Healthcare | $22.43 | 2025 | |
| Grifols USA, LLC | $21.58 | 2024 | Gamunex-C |
| Promius Pharma LLC | $18.92 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shamsuddin Khwaja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.